Search

Displaying results 2121 - 2130 of 2674 in total
  1. Target

    P2Y purinoceptor 14

    go.drugbank.com/bio_entities/BE0009825
    TargetHumans

    Receptor for UDP-glucose and other UDP-sugar coupled to G-proteins. Not activated by ATP, ADP, UTP or ATP

    Synonyms: UDP-glucose receptor, G protein-coupled receptor 105Function: G protein-coupled purinergic nucleotide receptor activity
  2. Drug

    Ansuvimab

    go.drugbank.com/drugs/DB16385
    Approved

    [A207646] Ansuvimab received FDA approval on December 21, 2020, and is currently marketed as Ebanga by Ridgeback Biotherapeutics, LP. Ansuvimab is just the second FDA-approved treatment for EVD.

  3. Drug

    Janssen COVID-19 Vaccine

    go.drugbank.com/drugs/DB15857
    ApprovedInvestigational

    The Janssen COVID-19 vaccine (Ad26.COV2.S) is a recombinant vaccine that contains an adenovirus serotype 26 (Ad26) vector expressing a stabilized SARS-CoV-2 spike protein. The vaccine was created in collaboration with Johnson and Johnson...

  4. Drug

    Ensulizole

    go.drugbank.com/drugs/DB11115
    Approved

    According to the FDA, the maximal approved concentration of ensulizole is 148 mM although concentrations ranging between 74 and 148mM can be found in commercial sunscreen products [A27151].

  5. Drug

    Nalmefene

    go.drugbank.com/drugs/DB06230
    ApprovedInvestigationalWithdrawn

    [L40684] The nasal spray formulation of nalmefene was approved by the FDA in May 2023.[L46511] … Nalmefene, a 6-methylene analogue of [naltrexone], is an opioid receptor antagonist.

  6. Drug

    Metoclopramide

    go.drugbank.com/drugs/DB01233
    ApprovedInvestigational

    [T683] Metoclopramide was initially approved by the FDA in 1980.[A184922]

    Categories: Dopamine D2 Receptor Antagonists
  7. Drug

    Glycyrrhizic acid

    go.drugbank.com/drugs/DB13751
    ApprovedInvestigational

    [A33062] From January 2014, glycyrrhizic acid as part of the licorice extract was approved by the FDA as an existing food sweetener.

  8. Drug

    Lasofoxifene

    go.drugbank.com/drugs/DB06202
    ApprovedInvestigationalWithdrawn

    It was initially developed as Oporia by Pfizer as a treatment for postmenopausal osteoporosis and vaginal atrophy, in which were both rejected for approval by FDA. … Lasofoxifene is a non-steroidal 3rd generation selective estrogen receptor modulator (SERM) that selectively binds to both ERα and ERβ with high affinity.

    Categories: Selective Estrogen Receptor Modulators
  9. Drug

    Olipudase alfa

    go.drugbank.com/drugs/DB12835
    ApprovedInvestigational

    [A251590] It was later approved by the European Commission on June 28, 2022 [L42740] and by the FDA on August 31, 2022.[L43145]

  10. Drug

    Risdiplam

    go.drugbank.com/drugs/DB15305
    ApprovedInvestigational

    [L15351,A216871] Risdiplam was approved by the FDA in August 2020 for the treatment of spinal muscular atrophy (SMA).